The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Specific MRP4 Inhibitor Ceefourin-1 Enhances Apoptosis Induced by 6-Mercaptopurine in Jurkat Leukemic Cells, but Not in Normal Lymphoblast Cell Line CRL-1991
Abstract
Background and objectives: The multidrug resistance protein 4 (MRP4) is a member of the ABC transporter, which has been extensively related to many types of cancer including leukemia. MRP4 overexpression and activity over the efflux of some chemotherapeutic drugs are the main causes of chemoresistance. 6-mercaptopurine (6-MP) is a chemotherapeutic drug widely used in the consolidation and maintenance phases of leukemia treatment. However, 6-MP is a substrate of MRP4, which decreases its chemotherapeutic efficacy. Current research is focused on the development of MRP4 inhibitors to combat chemoresistance by allowing the accumulation of the drug substrates inside the cells. To date, the only specific MRP4 inhibitor that has been developed is ceefourin-1, which has been reported to inhibit MRP4 in many cancer cells and which makes it an excellent candidate to enhance the activity of 6-MP in a combined treatment in vitro of leukemic cells. Materials and methods: in the present work, we determined the enhancing activity of ceefourin-1 on the antiproliferative and apoptotic effect of 6-MP in leukemic Jurkat cells by trypan blue assay and flow cytometry. Besides, we determined the 6-MP and ceefourin-1 binding sites into MRP4 by molecular docking and molecular dynamics. Results: ceefourin-1 enhanced the apoptotic activity of 6-MP in Jurkat cells, while in CRL-1991 cells both antiproliferative and apoptotic effect were significantly lower. Ceefourin-1 additively cooperates with 6-MP to induce apoptosis in leukemic cells, but normal lymphoblast CRl-1991 showed resistance to both drugs. Conclusion: ceefourin-1 and 6-MP cooperates to trigger apoptosis in leukemic Jurkat cells, but the full mechanism needs to be elucidated in further works. In addition, our perspective is to test the cooperation between ceefourin-1 and 6-MP in samples from patients and healthy donnors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have demonstrated that Ceefourin-1 is a highly specific inhibitor of ABCC459–62, effectively blocking the transport of its substrates such as 6-mercaptopurine (6-MP), cAMP, D-luciferin, and estradiol-17β-glucuronide (E217βG), without exerting detectable effects on related transporters MRP1, MRP2, MRP3 or MRP5.”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karran, P., & Attard, N. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2292 · Cited by 477
Research works printed but not linked: 33
- Berthier, 2019, Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics, Life Sci., 231, 116540, 10.1016/j.lfs.2019.06.015 · DOI
- Peng, 2008, Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine, Leuk. Res., 32, 799, 10.1016/j.leukres.2007.09.015 · DOI
- Norris, 2005, Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro, Mol. Cancer Ther., 4, 547, 10.1158/1535-7163.MCT-04-0161 · DOI
- Copsel, 2011, Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation, J. Biol. Chem., 286, 6979, 10.1074/jbc.M110.166868 · DOI · Paper page
- Perez, 2016, Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia, Oncotarget, 7, 33960, 10.18632/oncotarget.8986 · DOI
- Zhao, 2014, ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer, OncoTargets Ther., 7, 343
- Reid, 2003, The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs, Proc. Natl. Acad. Sci. USA, 100, 9244, 10.1073/pnas.1033060100 · DOI · Paper page
- Cole, 2014, Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present and Future, Annu. Rev. Pharmacol. Toxicol., 54, 95, 10.1146/annurev-pharmtox-011613-135959 · DOI · Paper page
- Leier, 1994, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates, J. Biol. Chem., 269, 27807, 10.1016/S0021-9258(18)46856-1 · DOI · Paper page
- Keppler, 2011, Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy, Drug Transp., 201, 299, 10.1007/978-3-642-14541-4_8 · DOI · Paper page
- Xie, 2011, Inactivation of Multidrug Resistance Proteins Disrupts Both Cellular Extrusion and Intracellular Degradation of cAMP, Mol. Pharmacol., 80, 281, 10.1124/mol.111.071134 · DOI
- Cheung, 2014, High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4), Biochem. Pharmacol., 91, 97, 10.1016/j.bcp.2014.05.023 · DOI · Paper page
- Krieger, 2008, Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4), Mol. Pharmacol., 74, 964, 10.1124/mol.107.043661 · DOI
- Smeets, 2005, Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites, Am. J. Physiol.-Ren. Physiol., 288, F327, 10.1152/ajprenal.00133.2004 · DOI · Paper page
- Maeno, 2009, Molecular Basis for Reduced Estrone Sulfate Transport and Altered Modulator Sensitivity of Transmembrane Helix (TM) 6 and TM17 Mutants of Multidrug Resistance Protein 1 (ABCC1), Drug Metab. Dispos., 37, 1411, 10.1124/dmd.109.026633 · DOI
- Strober, 2015, Trypan Blue Exclusion Test of Cell Viability, Curr. Protoc. Immunol., 21, A3.B.1
- Morris, 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem., 30, 2785, 10.1002/jcc.21256 · DOI · Paper page
- Becerra, E., Aguilera-Durán, G., Berumen, L., Romo-Mancillas, A., and García-Alcocer, G. (2021). Study of Endogen Substrates, Drug Substrates and Inhibitors Binding Conformations on MRP4 and Its Variants by Molecular Docking and Molecular Dynamics. Molecules, 26. · DOI
- Ravna, 2009, Molecular modeling studies of ABC transporters involved in multidrug resistance, Mini Rev. Med. Chem., 9, 186, 10.2174/138955709787316065 · DOI
- Usuki, 2017, Endoplasmic reticulum stress preconditioning modifies intracellular mercury content by upregulating membrane transporters, Sci. Rep., 7, 12390, 10.1038/s41598-017-09435-3 · doi:10.1038/s41598-017-09435-3
- Nurgali, 2018, Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?, Front. Pharmacol., 9, 245, 10.3389/fphar.2018.00245 · DOI · Paper page
- Singh, 2019, Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential, Oncotarget, 10, 3681, 10.18632/oncotarget.26978 · DOI
- Zou, 2021, Preparation, Characterization, Pharmacokinetic and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia, Int. J. Nanomed., 16, 1127, 10.2147/IJN.S290466 · doi:10.2147/ijn.s290466
- Haglund, S., Vikingsson, S., Almer, S., and Söderman, J. (2017). Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells—Effects on gene expression levels and thiopurine metabolism. PLoS ONE, 12. · DOI
- Poindessous, 2016, The effect of immunosuppressive molecules on T-cell metabolic reprogramming, Biochimie, 127, 23, 10.1016/j.biochi.2016.04.016 · DOI
- Abrol, 2019, A comprehensive review on benzothiazole derivatives for their biological activities, Int. J. Pharm. Sci. Res., 10, 3196
- Copsel, 2014, Multidrug resistance protein 4/ ATP binding cassette transporter 4: A new potential therapeutic target for acute myeloid leukemia, Oncotarget, 5, 9308, 10.18632/oncotarget.2425 · DOI
- Beis, 2015, Structural basis for the mechanism of ABC transporters, Biochem. Soc. Trans., 43, 889, 10.1042/BST20150047 · DOI · Paper page
- Ledderose, 2016, Cutting off the power: Inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?, Purinergic Signal., 12, 439, 10.1007/s11302-016-9510-y · DOI
- Insel, 2012, Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger, Acta Physiol., 204, 277, 10.1111/j.1748-1716.2011.02273.x · DOI · Paper page
- Zhang, 2008, Gene expression signatures of cAMP/protein kinase A (PKA)-promoted, mitochondrial-dependent apoptosis. Comparative analysis of wild-type and cAMP-deathless S49 lymphoma cells, J. Biol. Chem., 283, 4304, 10.1074/jbc.M708673200 · DOI
- Gao, 2010, A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling, J. Biol. Chem., 285, 28097, 10.1074/jbc.M110.116566 · DOI
- Cribbs, 2007, Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death, EMBO Rep., 8, 939, 10.1038/sj.embor.7401062 · DOI · Paper page
Cited by
Chen, J., Huang, H., Chen, C., Xia, G., Huang, H., Xiong, Y., Luo, P., Chen, Y., Li, J., Wen, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08818-x · Cited by 1
Metadata
- Authors
- Becerra, E., Berumen, L., Soto-Ontiveros, V., & García-Alcocer, G.
- Affiliations
- Posgrado en Ciencias Químico Biológicas, Facultad de Química, Universidad Autónoma de Querétaro, Cerro de las Campanas S/N, Querétaro 76010, Mexico
- Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2022-05-24
- Volume
- 58
- Issue
- 6
- Pages
- 695
- ISSN
- 1648-9144
- Cited by
- 4
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific MRP4 Inhibitor Ceefourin-1 Enhances Apoptosis Induced by 6-Mercaptopurine in Jurkat Leukemic Cells, but Not in Normal Lymphoblast Cell Line CRL-1991. https://app.cochat.ai/papers/10.3390/medicina58060695
- The paper
- Becerra, E., Berumen, L., Soto-Ontiveros, V., & García-Alcocer, G. (2022). Specific MRP4 Inhibitor Ceefourin-1 Enhances Apoptosis Induced by 6-Mercaptopurine in Jurkat Leukemic Cells, but Not in Normal Lymphoblast Cell Line CRL-1991. Medicina. https://doi.org/10.3390/medicina58060695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.